06/10/2026
What does it take to move a scientific discovery from the laboratory to people?
Join us October 7 at 1:30 PM PT for From Discovery to Impact: The Lenacapavir Journey, a special HANC webinar exploring the science, clinical research, and community engagement behind lenacapavir.
📅 October 7, 2026
🕐 1:30–2:30 PM PT
💻 HANC Webinar
Register here: https://tinyurl.com/LENimpact
Lenacapavir’s story begins with decades of NIH-funded basic research into HIV’s cone-shaped capsid protein and continues through clinical development, prevention research, and community advocacy.
We’ll hear from three leaders who bring different perspectives to this journey:
🔬 Dr. Wesley Sundquist, Chair of Biochemistry at the University of Utah, will share the foundational research that helped transform our understanding of HIV’s capsid and laid the groundwork for capsid-targeting approaches.
🧪 Dr. Moupali Das, Vice President of Clinical Development, HIV Prevention & Pediatrics at Gilead Sciences, will discuss the clinical development of lenacapavir, including the injectable formulation and the PURPOSE clinical trial program evaluating lenacapavir for HIV prevention.
🤝 Ms. Yvette Raphael, Co-founder and Executive Director of Advocacy for Prevention of HIV in Africa, will share her perspective on the essential role of community engagement and advocacy in HIV prevention research—and why the voices of people most affected by HIV must remain at the center of research and implementation.
Together, we’ll explore how basic science + clinical research + community partnership can come together to move discoveries from the laboratory into the real world.
